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Abstract
Purpose To assess safety and outcome of radiofrequency
ablation (RFA) and microwave ablation (MWA) as com-
pared to systemic chemotherapy and partial hepatectomy
(PH) in the treatment of colorectal liver metastases (CRLM).
Methods MEDLINE, Embase and the Cochrane Library
were searched. Randomized trials and comparative obser-
vational studies with multivariate analysis and/or matching
were included. Guidelines from National Guideline
Clearinghouse and Guidelines International Network were
assessed using the AGREE II instrument.
Results The search revealed 3530 records; 328 were selec-
ted for full-text review; 48 were included: 8 systematic
reviews, 2 randomized studies, 26 comparative observa-
tional studies, 2 guideline-articles and 10 case series; in
addition 13 guidelines were evaluated. Literature to assess
the effectiveness of ablation was limited. RFA ? systemic
chemotherapy was superior to chemotherapy alone. PH was
superior to RFA alone but not to RFA ? PH or to MWA.
Compared to PH, RFA showed fewer complications, MWA
did not. Outcomes were subject to residual confounding
since ablation was only employed for unresectable disease.
Conclusion The results from the EORTC-CLOCC trial,
the comparable survival for ablation ? PH versus PH
alone, the potential to induce long-term disease control and
the low complication rate argue in favour of ablation over
chemotherapy alone. Further randomized comparisons of
ablation to current-day chemotherapy alone should there-
fore be considered unethical. Hence, the highest achievable
level of evidence for unresectable CRLM seems reached.
The apparent selection bias from previous studies and the
superior safety profile mandate the setup of randomized
controlled trials comparing ablation to surgery.
Keywords Colorectal liver metastases (CRLM) 
Radiofrequency ablation (RFA)  Microwave ablation
(MWA)  Partial hepatectomy (PH)  Systemic
chemotherapy
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ZiNL Dutch National Health Care Institute
Introduction
Colorectal cancer is the second most common cause of
cancer-related death in developed countries and the third
most common malignancy worldwide [1]. Roughly 50% of
patients develop colorectal liver metastases (CRLM), yet
only a minority (10–15%) can undergo partial hepatectomy
(PH). Five-year survival following PH ranges between 31
and 58% in carefully selected patients [2, 3]. The remain-
der is usually offered chemotherapy and/or local tumour
ablation alone or in combination with PH. Especially
radiofrequency (RFA) and microwave ablation (MWA) are
commonly employed and widely available. Median overall
survival (OS) following systemic treatment nowadays
reaches 20–22 months in patients who receive sequential
chemotherapy regimens often with biological agents;
5-year survival remains\ 15% [4–8]. Five-year survival
following ablation varies between 17 and 53% [9–13].
Although recent studies [13–16] have reported similar
survival for patients treated with thermal ablation or PH,
interventional radiology and surgical oncology communi-
ties generally state that thermal ablation cannot be con-
sidered an alternative to PH. They recommend the use of
open, laparoscopic or percutaneous RFA and MWA for
small CRLM (B 3 cm) in patients who are unsuitable for
resection due to (1) an impaired general health status (age,
comorbidities), (2) a history of extensive abdominal sur-
gery, (3) the presence of lesions with an unfavourable
location or (4) an insufficient future liver remnant to resect
all lesions [11, 17, 18]. In light of these recommendations
the Dutch National Health Care Institute (ZiNL) and rep-
resentatives from the Dutch societies for interventional
radiology, surgical and medical oncology commissioned a
systematic review and meta-analysis with the following
research questions: (1) what is the evidence regarding
safety and effectiveness for RFA and MWA in the treat-
ment of CRLM? and (2) what is the status of RFA and
MWA in international guidelines?
Materials and Methods
Search Strategies
The search strategies and inclusion criteria were based on
the following PICOS question: P (population): patients
with resectable and unresectable CRLM; I (intervention):
RFA and MWA; C (comparison): for resectable disease PH
and for unresectable disease systemic chemotherapy; O
(outcomes): critical endpoints were OS, complications and
quality of life (QoL), important endpoints were disease-
free survival (DFS), local progression-free survival
(LPFS), and ablation-site recurrence rate (ASR); S (study
designs): (systematic reviews), randomized studies, con-
trolled studies, comparative observational studies with
multivariate analysis and/or matching, non-comparative
studies if an insufficient number of comparative studies
was found. To assess the relative importance of outcomes
(critical, important but not critical or limited) the Grading
of Recommendations, Assessment, Development and
Evaluation (GRADE) approach was used [19].
We used Cochrane systematic review methods to iden-
tify studies that met the inclusion criteria. MEDLINE,
Embase and the Cochrane Library (Cochrane Database of
Systematic Reviews, Database of Abstracts of Reviews of
Effectiveness, Health Technology Assessment database,
CENTRAL) were searched (last update September 26th
2017) using a combination of text words and medical
subheadings (search strategies: Table 3 online appendix).
No time limit was used.
Searches were limited to studies involving humans and
published in English or Dutch. Abstracts were only taken
into consideration when their methodological quality could
be sufficiently evaluated and data extraction could be
entirely completed. Studies also describing primary liver
tumours and/or non-colorectal liver metastases were only
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included if data about CRLM could be extracted sepa-
rately. Only studies reporting on the following outcomes
were considered: (1) critical outcomes: OS, QoL and
complications; (2) important outcomes: DFS, LPFS, ASR.
Study Selection and Quality Criteria
All retrieved studies were evaluated for inclusion by two
reviewers (JV, KHH) independently. First, studies were
evaluated on title and abstract. Studies potentially eligible
for inclusion were ordered in full text for a comprehensive
evaluation.
For the included studies, the methodological quality was
evaluated independently using the AMSTAR tool for sys-
tematic reviews and the risk of bias tool of the Cochrane
Collaboration for randomized trials and controlled studies.
For uncontrolled studies (including case series) the fol-
lowing criteria were judged: adequate definition of disease,
clear baseline characteristics, inclusion of a representative
cohort, adequate disease confirmation using validated
methods, standardized data collection and objective out-
come measurement.
All discrepancies were resolved by consensus. If no
consensus was reached, the opinion of a third researcher
(LGF) was the overriding factor.
Data Extraction
Data were extracted by one reviewer (KHH or LGF) and
checked by a second (JV). The results were displayed as
described in the article, allowing for recalculations based
on the data extracted from the article if needed.
Data Analysis
Based on clinical criteria, such as population, intervention,
control group and outcome, an assessment was made
whether the studies were sufficiently comparable to per-
form a meta-analysis. A random effects model was chosen,
unless there was no statistical heterogeneity. Individual
results were presented in a forest plot. The following
comparisons and outcomes allowed for a meta-analysis: (1)
RFA versus PH alone regarding OS, DFS, LPFS, 30-day
mortality and complications, and (2) RFA ? PH versus PH
alone regarding OS, DFS, LPFS and 60-day mortality. For
time-to-event outcomes (survival), the generic inverse
variance method was used. Only corrected hazard ratios
(HR; e.g. based on a multivariate analysis) were imputed.
For dichotomic results (complications), the Mantel–Haen-
szel method was used to calculate risk ratios (RR).
When C 10 studies were available for inclusion in the
meta-analysis a funnel plot was used to assess for
publication bias. The meta-analysis was conducted using
Review Manager 5.3.
Levels of Evidence
To appoint a level of evidence, the GRADE system was
used taking into account the quality assessment and the
results from data extraction [20, 21]. We classified the level
of evidence into 4 GRADE categories: high, moderate, low
and very low (Table 1). Quality elements evaluated for
downgrading were study limitations, inconsistency, indi-
rectness, imprecision and publication bias.
Two independent researchers graded the evidence levels
(JV, KHH). If consensus was not reached, the opinion of a
third independent researcher was decisive (LGF). The
reasons for appointing evidence levels were documented.
Guidelines
(Inter)national guidelines about RFA and MWA for CRLM
were searched in the following database: National Guide-
line Clearinghouse and Guidelines International Network
as well as on websites of (inter)national guideline organi-
zations and scientific societies. Two reviewers (JV, LGF)
selected and judged the guidelines using the AGREE II
instrument (Table 2 online appendix) [22]. If consensus
was not reached, the opinion of a third independent
researcher (KHH) was decisive.
Results
The literature search resulted in 3530 records. After
excluding 1121 duplicate papers and 459 documents writ-
ten in a non-English language, a total of 1950 unique ref-
erences remained (Fig. 1). Based on title and abstract 1622
references were excluded. A total of 328 articles were
selected for full-text review. This led to the exclusion of
280 articles for the following reasons: single cohort with-
out comparison (n = 115); wrong comparator, comparison,
intervention or outcome (n = 48); no separate results for
CRLM (n = 22); systematic review without quality
appraisal (n = 20); narrative review (n = 17); observational
study without matching or multivariate analysis (n = 16);
and other (n = 42) (Table 4 online appendix). A total of 48
articles were included: eight systematic reviews, two ran-
domized studies, twenty-six comparative observational
studies and ten case series. Two references were included
as guideline. Seven out of eight systematic reviews were
classified as high quality [1–3, 9, 23–25], one was judged
as poor quality [26] (Fig. 2).
Updated search resulted in three new comparative
observational studies [13, 27, 28].
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RFA
One randomized controlled trial (EORTC-CLOCC trial)
compared systemic chemotherapy (FOLFOX [Folinic acid,
Fluorouracil, Oxaliplatin] and from October 2005
FOLFOX ? bevacizumab) with or without RFA in 119
patients with unresectable CRLM (Fig. 3) [29]. Median
number of CRLM was 4 (systemic ? RFA) and 5 (sys-
temic alone); 25.0% of patients in systemic ? RFA group
had solitary metastases, 11.9% in the systemic only group.
Due to slow recruitment the trial was downgraded to a
phase II study.
Twenty-four observational studies compared RFA for
unresectable CRLM to PH for resectable disease (Fig. 4).
Fourteen studies compared RFA with surgery alone
[13, 30–42], eight studies compared RFA ? PH with PH
alone [13, 15, 16, 18, 27, 28, 43, 44], and four studies
compared RFA to RFA ? PH or PH alone [13, 45–47]. A
total number of 5020 patients were included in these
observational studies (RFA: N = 1103; RFA ? PH:
N = 541; PH alone: N = 3376). For none of these studies, it
could be excluded that therapy selection was based on
patient and/or tumour characteristics and/or physician
preference (confounding by indication). Moreover, the
methods used to describe outcomes were heterogeneous
and, although all included studies used multivariate
Table 1 Grading of Recommendations Assessment, Development and Evaluation (GRADE*) [19, 20]




RFA (± PH) ? chemotherapy is superior to chemotherapy alone 1 RCT (downgraded; serious imprecision)a Moderate
RFA ? chemotherapy is superior to chemotherapy alone 1 RCT (downgraded 2x; serious
indirectnessb and serious imprecision)a
Low
RFA (for unresectable CRLM) ? PH is equivalent to PH alone Observational comparative studies Very low
RFA alone (for unresectable CRLM) is inferior to PH alone Observational comparative studies Very low
MWA is equivalent to PH 1 RCT (downgraded; very serious risk of
bias)
Very low
MWA (for unresectable CRLM) ? PH is equivalent to PH alone One observational comparative study Very low
Complications RFA alone (for unresectable CRLM) is superior to PH Observational comparative studies Very low
Studies on RFA (for unresectable CRLM) ? PH versus PH alone
show conflicting results
Observational comparative studies –
MWA alone is equivalent to PH 1 RCT (downgraded; very serious risk of
bias)
Very low
Quality of life There are no comparative studies on the effect of RFA or MWA – –
*GRADE definitions: high quality—further research is very unlikely to change our confidence in the estimate of effect (randomized controlled
trials); moderate quality—further research is likely to have an important impact on our confidence in the estimate of effect and may change the
estimate (controlled trials, no randomization), low quality—further research is very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate (observational studies); very low quality—any estimate of effect is very uncertain (any
other type)
aserious imprecision: in case of low optimal information size (OIS; number of included patients did not meet sample size), dichotomous
outcomes, low number of events, wide confidence intervals with uncertainty about magnitude of effect, or when there is a lot of variation in the
effects among the participants in continious measures
bserious indirectness: very important differences in populations, interventions, outcome measures, or indirect comparisons
Fig. 1 Results of selection: effectiveness of thermal ablation versus
surgical resection or systemic chemotherapy in treating patients with
CRLM
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Fig. 2 Risk of bias of included reviews for RFA
Fig. 3 Risk of bias of Ruers et al. [29]
Fig. 4 Risk of bias of comparative observational studies for RFA
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analysis or data matching based on prognostic factors,
these factors differed from study to study. None of the
studies blinded patients or outcome assessors. In eleven
studies, data collection was retrospective.
Overall Survival
RFA Plus Chemotherapy Versus Chemotherapy Alone
The EORTC-CLOCC trial reported a 30-month OS of
61.7% (95% confidence interval (CI) 48.2–73.9%) for the
combination group versus 57.6% (95%CI 44.1–70.4%) in
the chemotherapy alone group [29]. After a median follow-
up of 9.7 years, OS was significantly better in the
RFA ? chemotherapy group (HR = 0.58; 95%CI
0.38–0.88) with an 8-year OS of 35.9 versus 8.9% for
chemotherapy alone [29]. In the RFA arm 27 out of 50
patients also underwent hepatic resection(s) which may
have confounded results.
RFA Versus PH Alone
Ten observational studies (N = 1824 reported corrected
hazard ratios for OS (Fig. 5) [13, 30, 31, 33–35, 37,
39, 45, 46]. Pooling of the results showed that RFA was
associated with an inferior OS (HR = 1.78; 95%CI
1.35–2.33)). Two other studies only reported non-corrected
HRs, treatment type was not associated with prognosis
based on univariate analysis [41, 47]. Adding these studies
to the meta-analysis did not substantially alter the results
(HR = 1.62; 95%CI 1.29–2.03).
Five articles allowed for pooling of OS results for
solitary metastases. Again, RFA was associated with a less
favourable outcome (HR = 1.77; 95%CI 1.18–2.65)
[31, 33–35, 39]. The corrected odds ratio as reported by
Aloia et al. also showed better results for PH alone (odds
ratio 3.22; 95%CI 1.74–5.96) [32].
RFA Plus PH Versus PH Alone
Seven observational studies (N = 1918 reported corrected
hazard ratios and allowed for pooling of OS results (Fig. 6)
[13, 15, 16, 18, 27, 45, 46]. No significant difference in OS
was found (HR = 1.24; 95%CI 0.84–1.84). One other
article reported only non-corrected hazard ratios, treatment
type was not associated with prognosis based on univariate
analysis. Adding this study to the meta-analysis did not
meaningfully alter the results: (HR = 1.27; 95%CI
0.90–1.81) [47]. Govindarajan et al. reported the OS for
recurrent CRLM, and did not detect a significant difference
between PH and PH ? RFA for both solitary CRLM
(p = 0.49) and multiple CRLM (p = 0.18) [43].
Adverse Events and Quality of Life
Ruers et al. reported one fatality (sepsis) in the
RFA ? chemotherapy group [29]. Ten observational
studies (N = 1795) comparing RFA and PH alone reported
post-procedural or 30-day mortality [30–32, 34–39, 47].
Meta-analysis did not show a difference (RR = 0.64;
95%CI 0.21–1.95), although the funnel plot did suggest
publication bias (Fig. 7). Of the observational studies
comparing RFA ? PH and PH alone, one study (N = 113)
reported 30-day mortality [39], two studies (N = 232)
reported 60-day mortality [18, 44] (Fig. 8) and two studies
(N = 709) reported 90-day mortality [15, 27] (Fig. 9). No
significant differences were detected (30-day: no events;
60-day: RR = 0.80; 95%CI 0.09–6.90; 90-day: RR = 1.02;
95%Cl 0.27–3.76). Govindarajan et al. reported two deaths
within 100-days post-resection in a group of 96 patients
versus no deaths in the combination group [43]. Hof et al.
Fig. 5 RFA versus PH alone: overall survival (OS)
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only reported the 30-day mortality rate for both interven-
tions (5 of 707 patients) [13].
In the EORTC-CLOCC trial, no significant difference in
chemotherapy-induced toxicity between the groups was
found [29]. In the observational studies comparing RFA
Fig. 6 RFA ? PH versus PH alone: overall survival (OS)
Fig. 7 RFA versus PH alone: 30-day mortality
Fig. 8 RFA ? PH versus PH alone: 60-day mortality
Fig. 9 RFA ? PH versus PH alone: 90-day mortality
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and PH alone, complications were more common after PH
compared to RFA (10 studies; RR = 0.47; 95%CI
0.28–0.78) (Fig. 10) [30, 31, 33–36, 39–41, 47]. Of the
observational studies comparing RFA ? PH and PH alone,
Faitot et al. reported serious adverse events in 28% after
PH (C grade 3) versus 13% in the combination group
(p = 0.017) [15]. Imai et al. reported major complications
in 18.6% in the PH alone group (C grade 3) versus 22%
after PF ? RFA (p = 0.656) [27]. Kim et al. reported
adverse events in 21% after PH (278 patients: 13 haem-
orrhage, 17 abscesses, 10 wound infections, 8 respiratory
failure, 11 ileus) versus 37% in the combination group (27
patients: 3 haemorrhage, 3 abscess, 3 wound infection, 1
respiratory failure) (p\ 0.001) [47]. Sasaki et al. and Hof
et al. didn’t report complications [13, 28].
Ruers et al. reported the effect of RFA on quality of life
using EORTC QLQ-C30 questionnaires [29]. With 110 out
of 119 patients included in the analysis, overall quality of
life decreased 27 points on average after the procedure to
partially restore (to 10 points under baseline) prior to
starting chemotherapy (4–8 weeks after RFA) and com-
pletely restored hereafter. No formal statistical comparison
was done.
Local Progression-Free Survival, Disease-Free
Survival and Ablation-Site Recurrence
RFA Plus Chemotherapy Versus Chemotherapy Alone
Ruers et al. reported a significantly longer median DFS of
16.8 months (95%CI 11.7–22.1) in the combination group
versus 9.9 months (95%CI 9.3–13.7) in the chemotherapy
alone group corresponding to a HR of 0.63 (95%CI
0.42–0.95, p = 0.025) [29]. The percentage of patients
treated for the first progression was comparable between
both arms, 37 out of 42 patients (88.1%) in the combination
treatment group and 46 out of 53 patients (86.8%) in the
systemic treatment group. The long-term results, confirmed
an overall DFS favouring RFA ? chemotherapy (HR 0.57;
95% CI 0.38–0.85; p = 0.005). The 8-year DFS for
RFA ? chemotherapy versus chemotherapy alone was
22.3% (95%CI 12.7–33.7) versus 2.0% (95%CI 0.2–9.0)
[29].
RFA Versus PH Alone
Three and five observational studies (N = 406 and
N = 1253), respectively, reported corrected hazard ratios
for DFS [30, 36, 37, 46, 47] and LPFS [34, 40, 45]
(Figs. 11, 12). RFA was inferior to PH regarding LPFS and
DFS (HR = 5.36 [95%CI 1.64–17.52] and 1.49 [95%CI
1.23–1.81], respectively). One study specifically included
patients with solitary CRLM; again PH was superior
(HR = 4.61; 95%CI 1.16–18.32) [34]. Most studies did not
report corrected data for the number of recurrences.
However, Gleisner et al. performed a matched-control and
propensity score analysis [46]. At 1 year any disease
recurrence was more commonly detected after RFA com-
pared to PH alone (66 vs. 24%; p\ 0.001) with a high rate
of ASR after RFA (41 vs. 2%; p\ 0.001). Lee et al. also
included a propensity score analysis; ASR rate was higher
after RFA compared to resection (p = 0.021) [36].
RFA Plus PH Versus PH Alone
Four and two observational studies (N = 1261 and
N = 465), respectively, reported corrected hazard ratios for
DFS [15, 27, 46, 47] and LPFS [16, 45] (Figs. 13, 14).
RFA ? PH was associated with a poor LPFS compared to
PH alone (HR = 1.64; 95%CI 1.22–2.20). No significant
Fig. 10 RFA versus PH alone: complication rate
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difference in DFS between RFA ? PH versus PH alone
was found (HR = 1.14; 95%CI 0.82–1.60). One study used
a matched-control and propensity score analysis which
revealed a higher rate of overall and treatment site recur-
rences after RFA at 1 year (overall 61 vs. 24%; p\ 0.001
and ASR 10 vs. 2%; p\ 0.001) [46]. Sasaki et al. and Hof
et al. didn’t report corrected hazard ratios for LPFS or DFS
[13, 28].
MWA
One randomized controlled trial (RCT) compared MWA to
hepatectomy in 30 patients with resectable CRLM
(Fig. 15) [48]. The absence of an intention-to-treat analysis
makes this study at high risk of bias; 25% (10/40) of the
randomized patients were not included in the analysis and
the precise randomization method remains unclear.
One observational study compared MWA ? PH to PH
alone in 53 consecutive patients with at least 5 bilobar
Fig. 11 RFA versus PH alone: disease-free survival (DFS)
Fig. 12 RFA versus PH alone: local progression-free survival (LPFS)
Fig. 13 RFA ? PH versus PH alone: disease-free survival (DFS)
Fig. 14 RFA ? PH versus PH alone: local progression-free survival (LPFS)
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CRLM [49]. MWA was performed for unresectable le-
sions. Another observational study compared a group of 20
patients who underwent MWA for multiple unre-
sectable CRLM with two historical cohorts: 36 patients
who had resection and 25 patients who only received
systemic treatment [50]. Both studies are at risk of bias due
to the absence of a randomization process and the retro-
spective data collection (Fig. 16).
Finally, an additional number of ten case series were
included (N = 689) (Fig. 17) [51–60]. In seven of these,
the majority of patients underwent combined resec-
tions ? MWA [51–55, 57, 59]. Seven studies have a high
risk of bias due to retrospective data collection and/or
contamination of results after complementary PH
[51–55, 57, 59]; in the three other studies risk of bias
remains unclear because selection bias cannot be excluded
[56, 58, 60]. Only two studies separately reported results
for solitary CRLM [56, 58]. Last updated search revealed
no extra articles for MWA.
Overall Survival
Shibata et al. reported a 3-year OS of 23% after hepatec-
tomy and 14% after MWA [48]. Median OS was 25 versus
27 months (p = 0.83).
Engstrand et al. reported a 4-year OS of 41% for the
MWA group versus 4% in the historical cohort treated with
chemotherapy alone [50]. Treatment modality was found to
be a prognostic factor in multivariate analysis (HR = 0.56;
95%CI 0.33–0.96). The 4-year OS in the PH alone cohort
was 70%, but no formal statistical comparison was
reported.
Tanaka et al. did not detect a significant difference in OS
between MWA ? PH versus PH alone (3-year OS: 50.9 vs.
48.8%) [49]. Median OS was 39 months after PH and
Fig. 15 Risk of bias of Shibata et al. [48]
Fig. 16 Risk of bias of observational studies for MWA
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28 months after MWA ? PH. In multivariate analysis,
MWA was no prognostic factor for OS.
Median OS in five case series ranged between 24 and
36 months [53, 54, 57–59]. The reported 3-,4- and 5-year
OS varied between 35–79% [53, 54, 59, 60], 35–58%
[52, 55] and 17–18% [53, 59], respectively.
Mortality, Adverse Events and Quality OF Life
Both Shibata et al. and Tanaka et al. did not detect any
mortality after MWA or PH within 60 days after the pro-
cedure [48, 49]. Reported mortality in the case series ran-
ged from 0 to 2% [55, 57, 59]. Shibata et al. reported
complications in 2/14 patients in the MWA group (1 liver
abscess, 1 biliary fistula) and in 3/16 in the PH group (1
intestinal obstruction, 1 biliary fistula, 1 wound infection)
(p = 0.87) [48]. Tanaka et al. found complications in 6/37
patients undergoing liver PH versus 3/16 in the combina-
tion group (no p = value reported) [49]. In the case series,
the documentation of complications was heterogeneous.
Complication rates varied between 0 and 54%
[51, 52, 54, 56, 57, 59]. No studies reported the effect on
quality of life.
Disease-Free Survival and Ablation-Site Recurrence
Shibata et al. reported a median DFS of 13.3 months fol-
lowing PH versus 11.3 months following MWA [48].
Tanaka et al. did not detect a significant difference in DFS
(4-year DFS: 39 vs. 35%; p = 0.86) [49]. After a median
follow-up of 21 months, 28/34 (19 in the liver) patients in
the PH group had a recurrence versus 11/15 (9 in the liver)
in the MWA group after a median follow-up of 19 months.
Eng et al. reported a 3.5-year DFS of 19% [52]. Stattner
et al. found a 3-year DFS of 22% for the entire MWA
group and 32% for the MWA alone subgroup [59]. Two
studies found a median DFS of 8 and 12 months [57, 59].
Groeschl et al. reported a 3- and 5-year DFS of 34 and 9%,
respectively [53]. In a second series Groeschl et al. found a
3-year DFS of 0% [54]. Overall recurrence was present in
39–72% [52–54, 57, 59]. In 8 case series ASR varied
between 2 and 30% [51–54, 56–59].
Guidelines
The search for guidelines resulted in 15 references, out of
which two were excluded because they were updated by a
more recent version [61, 62]. Thirteen references were
evaluated based on their full text; all were included and
assessed according to the AGREE II instrument (Table 2
online appendix) [63–75]. In 4 guidelines RFA and MWA
was not mentioned [63–66]. In 1 guideline RFA was
mentioned but without clear recommendations [67]. The
American College of Radiology (ACR) guideline does not
include specific recommendations, but RFA was described
as unsuitable for CRLM, although scientific support for this
statement is lacking [68]. The US National Comprehensive
Cancer Network (NCCN) guidelines do not provide well-
Fig. 17 Risk of bias of case series for MWA
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defined recommendations for RFA and MWA, although
they do write the following: ‘‘The panel does not consider
ablation to be a substitute for resection in patients with
completely resectable disease. In addition, resection or
ablation (either alone or in combination with resection)
should be reserved for patients with disease that is com-
pletely amenable to local therapy. Use of surgery, ablation,
or the combination, with the goal of less-than-complete
resection/ablation of all known sites of disease, is not
recommended’’ [69, 70]. References to the EORTC-
CLOCC trial and to several observational studies were
used to support these statements [3, 29, 46, 76–80]. The
European Society for Medical Oncology (ESMO) consid-
ers RFA suitable for CRLM\ 4 cm if surgery is contra-
indicated and refers to the EORTC-CLOCC trial and a
systematic review [29, 71, 78]. The UK National Institute
for Health and Care Excellence (NICE) guideline considers
the current evidence on safety and efficacy adequate to
support the use of this procedure in patients unfit or
otherwise unsuitable for hepatic resection, or in those who
have previously had hepatic resection, provided that nor-
mal arrangements are in place for clinical governance,
consent and audit [72]. The Scottish Intercollegiate
Guidelines network (SIGN) commends that ablation should
be considered for CRLM [73, 81]. The Belgian Health Care
Knowledge Center (KCE) recommends the use of RFA in
combination with PH to preserve sufficient future liver
remnant and refers to the NICE, SIGN and CCO guidelines
[74]. The most comprehensive recommendations were
reported in the Dutch Comprehensive Cancer Centre
(IKNL) guideline: thermal ablation cannot be considered a
substitute for resection, but represents a suitable treatment
option for unresectable CRLM if the goal is a complete
eradication of all lesions with curative intent [75]. Percu-
taneous ablation can be considered for patients who are less
suitable for surgery because of high-age, comorbidity,
unfavourable location or a history of extensive abdominal
surgery. The ablation technique of the first choice is RFA.
MWA can be considered a good alternative, especially for
lesions in proximity of large blood vessels where heatsink,
when heat is carried away by the flowing blood, may
enable tumour cells to survive after RFA. IKNL refers to
the EORTC-CLOCC trial, the Cochrane review and several
observational studies [3, 26, 29, 82–85].
Discussion
Contradictory to the many available comparative obser-
vational studies and case series on thermal ablation for
CRLM, the literature to reliably assess its effectiveness
compared to chemotherapy and surgery is limited.
Although one RCT was identified for RFA [29], GRADE
valuation required downgrading the quality of evidence
regarding OS. When comparing RFA
(± PH) ? chemotherapy to chemotherapy alone, quality
was downgraded to moderate, especially because both the
optimal information size (OIS; number of included patients
did not meet sample size) and the reduced relative risk
(RRR = 100 * [1 - upper limit of the 95%CI for the HR
(0.88)] = 12%) was too low (serious imprecision; Table 1).
When comparing RFA ? chemotherapy to chemotherapy
alone, quality was further downgraded to low, because a
substantial part of the ablated patients also underwent PH
(serious indirectness). However, the remarkable differences
in 8-year OS (8.9 vs. 35.9%) and 8-year DFS (22.3 vs.
2.0%) seem to validate the eradication of all macroscopi-
cally visible CRLM and to justify the adoption of thermal
ablation for unresectable CRLM for this indication [29].
The very serious risk of bias of the one MWA trial required
downgrading to very low-quality evidence.
Comparing PH alone for resectable lesions with RFA for
unresectable lesions, RFA was associated with significantly
fewer complications but also with an inferior survival. In
contrast, RFA in addition to PH for patients with unre-
sectable disease, resulted in a comparable survival to
resection alone for patients with resectable disease. In other
words, for patients with unresectable disease, in whom
palliative chemotherapy used to denote the only treatment
option, RFA is able to offer patients a DFS and OS com-
parable to or approaching that of surgical candidates. Out
of the eight studies published after 2012, seven showed a
similar OS when comparing ablation (± PH) to PH alone
(Figs. 5, 6), which may advert to ablative technique
improvements. Although MWA compared to chemother-
apy alone was associated with a superior OS for patients
with unresectable CRLM, this is based on a single retro-
spective study at risk of bias due to the unclear random-
ization process, which seriously demotes quality of
evidence [50].
In contrast to RFA, the number of comparative studies
for MWA was limited. For this reason, we incorporated
more restrictions for the RFA studies, including only RCTs
and observational studies that performed either case
matching or multivariate analysis for prognostic factors.
The included observational studies were by definition all
confounded by indication, since ablation was only per-
formed for unresectable lesions. Reasons for choosing
ablation over PH were comorbidity (0–41%), inadequate
future liver remnant and/or technical factors such as diffi-
cult anatomical location (5–67%), patient’s choice
(0–61%) or extrahepatic disease for studies where this was
no exclusion criterion (0–19%). Two other methods to
adjust for confounding, namely restricting inclusion to
patients from one prognostic category (for example bilobar
CRLM) or stratification into subgroups were not allowed,
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because these methods only take one prognostic factor into
account. All outcome measures were heterogeneously
reported and follow-up periods ranged between 19 and
61 months in observational studies on RFA. The docu-
mentation of tumour load and disease status was strongly
variable as were the definitions of progression-, recurrence-
and disease-free survival.
The reporting of complications was heterogeneous,
which is why it is difficult to identify the most frequent
complications for thermal ablation. Of the 24 observational
studies, only two were published prior to 2008. In recent
years, several technical advancements were implemented
in the field of RFA, although the same can be assumed for
surgical techniques. The impact of these two older reports
on the global results is probably limited. For MWA this
effect may be greater, because the only RCT was published
in 2000 and one of two observational studies in 2006.
Although technical factors such as an unfavourable
anatomical location were used to choose for thermal
ablation, clear definitions for resectability were not pro-
vided in any of the included studies, with the exception of
Ruers et al., who defined resectability as ‘‘the possibility to
completely resect all CRLM’’ [29]. For this reason, sub-
group analysis was impossible and the risk for potential
confounding by indication remains high. In the thermal
ablation studies, the number of procedures necessary to
reach local control was heterogeneously reported.
At the time of literature review, there was only one
series comparing RFA to MWA for CRLM [86]. Of 243
patients there were no differences regarding OS and ASR
between RFA and MWA (p = 0.559 and 0.078, respec-
tively), although the complication rate for peribiliary
CRLM was higher after MWA (p = 0.002).
Conclusions drawn from previous meta-analyses are
comparable to ours with regard to patients with
resectable CRLM, but differ for patients with unre-
sectable disease. The review from Sutherland et al. [25]
(published in 2006) was probably too old to find suffi-
ciently relevant studies. Belinson et al. [2] and Cirocchi
et al. [3] concluded: ‘‘Evidence from the included studies
are insufficient to recommend RFA for a radical oncolog-
ical treatment of CRLMs’’. Gurusamy et al. did not find
any RCTs [9]. Bala et al. [1] and Loveman et al. [23] found
one RCT for MWA (Shibata et al. [48] published in 2000)
and concluded: ‘‘Evidence is insufficient to show whether
microwave coagulation brings any significant benefit in
terms of survival or recurrence compared with conven-
tional surgery for CRLM patients’’. Smith et al. [24] did
not assess RFA separately. Pathak et al. [26] were more
positive in their conclusions, although their analysis pri-
marily included case series.
The results from this analysis should be judged with
caution. Although systematically obtained, there are no
guarantees that all available evidence was identified. Fur-
thermore, the inclusion of observational studies increases
the risk for publication bias, for which objective indications
were detected for the complication rate. Although (for
RFA) only studies using randomization, matching or mul-
tivariate analysis was included, this does not exclude
residual confounding.
To conclude, this article is the first systematic review
that supports the widespread adoption of thermal ablation
to treat small unresectable CRLM. The (1) recently pub-
lished long-term survival results from the EORTC-CLOCC
trial [29], the (2) comparable survival results after ablation
versus resection for the series reported after 2012, the (3)
comparable survival after ablation ? resection versus
resection alone, the (4) potential to induce long-term dis-
ease control and the (5) low complication rates all argue in
favour of thermal ablation over chemotherapy alone. Fur-
ther randomized comparisons of thermal ablation with
curative intent to current-day palliative chemotherapy
alone should therefore be considered unethical. As a con-
sequence, the highest achievable evidence level for unre-
sectable CRLM seems to have been reached.
Although ablation for unresectable CRLM seems infe-
rior to PH for resectable lesions, the lower complication
rate combined with the apparent selection bias stresses the
need to conduct a randomized controlled trial. Currently,
PH for resectable CRLM is being challenged by thermal
ablation in a large multicentre, phase III, randomized
controlled trial (COLLISION trial; NCT03088150). This
study assesses overall- and disease-free survival, time to
(local) progression, primary and assisted technique efficacy
rates, adverse events, quality of life and incremental costs.
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